Vetoquinol Sa operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vetoquinol Sa with three other
pharmaceutical manufacturers in Europe:
Swedish Orphan Biovitrum AB (publ)
sales of 4.50 billion Swedish Kronor [US$533.45 million]
of which 41%
was Haemophilia: Elocta),
Dechra Pharmaceuticals PLC
of the United Kingdom
(£247.56 million [US$326.17 million]
of which 76%
was European Pharmaceuticals), and
based in Russia
(26.76 billion Russian Rubles [US$444.23 million]
During the year ended December of 2016, sales at
Vetoquinol Sa were 350.35 million Euro (US$413.15 million).
increase of 2.3%
versus 2015, when the company's sales were 342.61 million Euro.
This was the fifth consecutive year of sales increases at Vetoquinol Sa
(and since 2011, sales have increased a total of 23%).
Sales of Europe saw an increase
that was more than double the company's growth rate: sales were up
30.3% in 2016, from
204.29 million Euro to 266.16 million Euro.
Vetoquinol Sa also saw significant increases in sales in
Americas (up 21.3% to 135.50 million Euro)